LY
Lyell Immunopharma, Inc.
LYEL · NASDAQ
$11.01 +4.31% (+$0.46)
1M -25.31%
Market Cap $269.8M
P/E Ratio -
Div. Yield -
ROE 91.62%
Piotroski F-Score Weak
1/9Valuation
50 /100
Fair P/S 9,992.33x
P/B 1.15x
P/E N/A
Growth
0 /100
Declining Rev. growth 92.48%
Book val. growth 33.22%
EPS growth N/A
Profitability
0 /100
Weak Gross margin 8,537.04%
Net margin 920,285.00%
Op. margin 711,330.00%
Quality
0 /100
Poor ROIC 70.80%
ROE 91.62%
ROA 79.86%
Debt
100 /100
Low Debt/Equity 0.16x
Current ratio 5.36x
Int. coverage N/A
Stability
21 /100
Unstable Beta -0.07x
Rev. volatility 31.09%
EPS volatility 630.98%
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o LYEL
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Lynn Seely
Employees
161
Headquarters
South San Francisco
Nadchodzące wydarzenia
10 LIS
Earnings
Upcoming earnings report